肝海绵状血管瘤个性化介入治疗的临床疗效分析

Analysis of Clinical Curative Effect of Personalized Interventional Therapy on Hepatic Cavernous Hemangioma

目的探讨采用经动脉栓塞或经动脉栓塞联合经皮经肝穿刺瘤内注射硬化治疗不同血供特点肝海绵状血管瘤（CHL）的临床疗效。方法对2004年2月-2013年4月收治的86例不同血供特点CHL患者经股动脉插管行平阳霉素碘化油乳化剂栓塞或经动脉栓塞联合经皮经肝穿刺瘤内注射平阳霉素碘化油乳化剂硬化治疗。结果 45例（52.3%）瘤体缩小超过50%,26例（30.2%）瘤体缩小20%~50%,11例（12.8%）瘤体缩小不足20%,4例（4.7%）瘤体病灶无明显变化,所以患者无严重并发症发生。结论对于不同血供特点CHL采用个性化介入治疗效果明显,是一种安全有效的治疗方法。

Objective To explore the clinical efficacy of transcatheter arterial embolization or transcatheter arterial embolization combined with percutaneous transhepatic sclerotherapy injection for hepatic cavernous hemangioma with different blood supply. Methods Eighty-six patients with hepatic cavernous hemangioma with different blood supply received femoral artery pingyangmycin iodized oil embolization or transcatheter arterial embolization combined with percutaneous transhepatic injection of pingyangmycin iodized oil embolization from February 2004 to April 2013. Results Forty-five cases（52.3%） of tumor decreased by over 50%; 26（30.2%） decreased by about 20% to 50%; 11（12.8%） decreased by less than 20%; and 4（4.7%） had no signifficant change in the tumor diameter. Patients did not have serious complications. Conclusion The ef ect of individualized intervention for hepatic cavernous hemangioma with dif erent blood supply is obvious, and it is a safe and ef ective therapeutic method.